Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Company Summary
Based in Carlsbad, CA, Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. The company leverages this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases, for itself and its partners.
Ionis has phase III studies ongoing for nine medicines (internal as well as partnered) across multiple indications. These include tofersen for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations; pelacarsen for cardiovascular disease (CVD) due to elevated Lp(a) levels; olezarsen for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG); eplontersen for ...
Company Summary
Based in Carlsbad, CA, Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. The company leverages this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases, for itself and its partners.
Ionis has phase III studies ongoing for nine medicines (internal as well as partnered) across multiple indications. These include tofersen for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations; pelacarsen for cardiovascular disease (CVD) due to elevated Lp(a) levels; olezarsen for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG); eplontersen for TTR amyloidosis; ulefnersen (ION363) for ALS, with mutations in the fused in sarcoma gene (FUS); donidalorsen for hereditary angioedema (HAE); bepirovirsen for chronic hepatitis B virus (CHB); IONIS-FB-LRx for immunoglobulin A nephropathy (IgAN); and zilganersen in Alexander’s disease.
Ionis currently has five partnered marketed drugs in its portfolio — Spinraza for spinal muscular atrophy (SMA), Qalsody in SOD1-ALS, Wainua for treating polyneuropathy caused by hereditary TTR (hATTR) amyloidosis (ATTRv-PN or hATTR-PN), Tegsedi in hATTR amyloidosis and Waylivra for genetically confirmed FCS. While the company receives royalties on net sales for Spinraza, Qalsody and Wainua, it earns distribution fees for Tegsedi and Waylivra sales.
Spinraza and Qalsody are licensed to Biogen, while Wainua is marketed in partnership with AstraZeneca. Tegsedi and Waylivra are sold by Ionis through a distribution agreement with Swedish Orphan Biovitrum AB (Sobi), signed in 2021.
In 2023, Ionis generated $787.6 million in revenues, up 34% year over year. Total revenues included $308.6 million in commercial revenues and $479 million in research and development (R&D) revenues (upfront payments, milestone payments and license fees from partnered medicines).
General Information
Ionis Pharmaceuticals, Inc
2855 GAZELLE COURT
CARLSBAD, CA 92010
Phone: 760-931-9200
Fax: 760-603-2700
Web: http://www.ionispharma.com
Email: info@ionisph.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.17 |
Current Year EPS Consensus Estimate | -3.69 |
Estimated Long-Term EPS Growth Rate | 8.40 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 49.90 |
52 Week High | 54.44 |
52 Week Low | 35.95 |
Beta | 0.39 |
20 Day Moving Average | 957,215.62 |
Target Price Consensus | 61.45 |
4 Week | -2.95 |
12 Week | 22.41 |
YTD | -5.75 |
4 Week | -8.14 |
12 Week | 15.88 |
YTD | -15.86 |
Shares Outstanding (millions) | 146.21 |
Market Capitalization (millions) | 6,971.35 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 25.00% |
vs. Previous Quarter | 54.08% |
vs. Previous Year | 19.68% |
vs. Previous Quarter | 89.08% |
Price/Book | 26.44 |
Price/Cash Flow | NA |
Price / Sales | 8.57 |
6/30/24 | -115.66 |
3/31/24 | -107.64 |
12/31/23 | -90.29 |
6/30/24 | -12.83 |
3/31/24 | -13.17 |
12/31/23 | -12.39 |
6/30/24 | 7.61 |
3/31/24 | 7.37 |
12/31/23 | 5.90 |
6/30/24 | 7.51 |
3/31/24 | 7.28 |
12/31/23 | 5.83 |
6/30/24 | -44.90 |
3/31/24 | -49.49 |
12/31/23 | -46.32 |
6/30/24 | -44.90 |
3/31/24 | -49.49 |
12/31/23 | -46.32 |
6/30/24 | -43.36 |
3/31/24 | -46.88 |
12/31/23 | -42.40 |
6/30/24 | 1.80 |
3/31/24 | 2.03 |
12/31/23 | 2.70 |
6/30/24 | 0.41 |
3/31/24 | 0.36 |
12/31/23 | 0.36 |
6/30/24 | 4.67 |
3/31/24 | 4.15 |
12/31/23 | 3.18 |
6/30/24 | 82.37 |
3/31/24 | 80.59 |
12/31/23 | 76.07 |